Unknown

Dataset Information

0

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.


ABSTRACT: Thirty-six patients with type 2 diabetes mellitus (T2DM) were randomized 1:1:1 to receive a once-daily oral dose of placebo or 150 or 300 mg of the dual SGLT1/SGLT2 inhibitor LX4211 for 28 days. Relative to placebo, LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose reabsorption; markedly and significantly improved multiple measures of glycemic control, including fasting plasma glucose, oral glucose tolerance, and HbA(1c); and significantly lowered serum triglycerides. LX4211 also mediated trends for lower weight, lower blood pressure, and higher glucagon-like peptide-1 levels. In a follow-up single-dose study in 12 patients with T2DM, LX4211 (300 mg) significantly increased glucagon-like peptide-1 and peptide YY levels relative to pretreatment values, probably by delaying SGLT1-mediated intestinal glucose absorption. In both studies, LX4211 was well tolerated without evidence of increased gastrointestinal side effects. These data support further study of LX4211-mediated dual SGLT1/SGLT2 inhibition as a novel mechanism of action in the treatment of T2DM.

SUBMITTER: Zambrowicz B 

PROVIDER: S-EPMC3400893 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

Zambrowicz B B   Freiman J J   Brown P M PM   Frazier K S KS   Turnage A A   Bronner J J   Ruff D D   Shadoan M M   Banks P P   Mseeh F F   Rawlins D B DB   Goodwin N C NC   Mabon R R   Harrison B A BA   Wilson A A   Sands A A   Powell D R DR  

Clinical pharmacology and therapeutics 20120704 2


Thirty-six patients with type 2 diabetes mellitus (T2DM) were randomized 1:1:1 to receive a once-daily oral dose of placebo or 150 or 300 mg of the dual SGLT1/SGLT2 inhibitor LX4211 for 28 days. Relative to placebo, LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose reabsorption; markedly and significantly improved multiple measures of glycemic control, including fasting plasma glucose, oral glucose tolerance, and HbA(1c); and significantly lowered serum triglyc  ...[more]

Similar Datasets

| S-EPMC4831906 | biostudies-literature
| S-EPMC7085338 | biostudies-literature
| S-EPMC6124499 | biostudies-literature
| S-EPMC5131876 | biostudies-literature
| S-EPMC2713651 | biostudies-literature
| S-EPMC4210070 | biostudies-literature
| S-EPMC6851837 | biostudies-literature
| S-EPMC2584188 | biostudies-literature
| S-EPMC3889318 | biostudies-literature
| S-EPMC7670540 | biostudies-literature